AbCellera Biologics Q3 2026 earnings

ABCL · 2026-11-09 16:22 AMC ET · 8-K on SEC

Revenue and operating expenses improved year-over-year, and the company raised $200 million to expand liquidity to approximately $900 million.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$10.6 million+18.5%+162.2%Ex. 99.1, income statement
EPS (GAAP)$(0.13)+31.6%+28.0%Ex. 99.1, income statement
Net income$(40.8) million+28.6%+26.4%Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $63.9 million (-25.0%)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge not stated in the 8-K

KPIs

MetricActualPrior quarterPrior yearChange
Total cash and marketable securities$764.4 million$540.1 million$533.8 million+41.5% YoY, +41.5% QoQ
Available liquidityover $890 millionover $675 millionover $565 million+31.9% YoY, +31.9% QoQ
Downstream programs343544-22.7% YoY, -2.9% QoQ

Guidance

not stated in the 8-K

What drove it

  • Revenue story Research fees increased 19.6% YoY to $10.5 million; licensing and royalty revenue decreased 34.8% YoY to $90,000.
  • EPS story Net loss per share improved year-over-year due to lower operating expenses and a narrower net loss.
  • One-off check not stated in the 8-K

The good

  • Revenue increased year-over-year (+18.5%)
  • Operating expenses decreased year-over-year (-25.0%)
  • Liquidity expanded to over $890 million following $200 million capital raise

The bad

  • Net loss remains significant at $(40.8) million
  • Downstream programs decreased year-over-year (44 to 34)

The ugly

  • none

Open questions

  • The filing does not disclose the tax rate or reconciliation of GAAP to adjusted figures.
  • The filing does not provide guidance for future quarters.
Full release

AbCellera Biologics (ABCL) earnings release, November 9, 2026

AbCellera Biologics Inc. (ABCL) · Form 8-K, Item 2.02 · Filed · SEC filing

NEWS RELEASE

AbCellera Reports Q3 2026 Business Results

11/9/2026

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“This was a transformative quarter for AbCellera, highlighted by strong clinical execution and balance sheet expansion. Positive top-line Phase 2 results for ABCL635 demonstrated an efficacy and tolerability profile that has potential to redefine the treatment of hot flashes. On the strength of this data, we raised $200 million, bringing our available liquidity to approximately $900 million,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “Together with the top-line Phase 1 readout of ABCL575 and the addition of three new pipeline programs, ABCL992, ABCL385, and ABCL646, we have delivered on all corporate priorities for 2026.”

Q3 2026 Business Summary and Program Updates

● Announced positive top-line Phase 2 clinical trial data for ABCL635 that demonstrated significant reductions in the frequency and severity of moderate and severe vasomotor symptoms (VMS), a favorable tolerability profile, and significant improvements in sleep and patient global impression of change (PGI-C). AbCellera expects to initiate late-stage development for menopausal VMS in 2027. AbCellera is also expanding the indications for ABCL635 to include VMS caused by hormone suppression associated with breast and prostate cancer treatment. The initiation of clinical trials in these two populations is expected in 2027.

● Completed a $200 million offering of common shares and pre-funded warrants.

● Continued to advance ABCL386 and ABCL688 through IND-enabling activities.

● Advanced the following three new programs in IND-enabling activities:

● ABCL992, an investigational antibody drug candidate that is a next-generation half-life extended analog of ABCL635 for the treatment of VMS;

● ABCL385, an investigational antibody drug candidate for an undisclosed indication in oncology; and

● ABCL646, a potential first-in-class investigational antibody antagonist of an undisclosed ion channel target for the treatment of an undisclosed indication.

● Generated a net loss of $40.8 million, compared to a net loss of $57.1 million in Q3 2025.

● Ended the quarter with over $790 million in total cash balances and marketable securities, and over $890 million in total available liquidity to execute on AbCellera’s strategy.¹

Subsequent Event

● Announced top-line data for the Phase 1 clinical trial of ABCL575, an investigational antibody drug candidate targeting OX40 ligand for the treatment of atopic dermatitis and other autoimmune conditions. The Phase 1 study met all endpoints, demonstrating a favorable tolerability profile and a pharmacokinetic profile that supports an extended dosing interval. AbCellera currently does not plan to develop ABCL575 past Phase 1.

Discussion of Q3 2026 Financial Results

● Revenue – Total revenue was

$10.6 million, compared to $9.0 million in Q3 2025.

● Research & Development (R&D) Expenses – R&D expenses were $43.5 million, compared to $55.0 million in Q3 2025.

● Sales, General, & Administrative (SG&A) Expenses – SG&A expenses were $13.6 million, compared to $25.0 million in Q3 2025.

● Net Loss – Net loss of $40.8 million, or $(0.13) per share on a basic and diluted basis, compared to net loss of $57.1 million, or $(0.19) per share on a basic and diluted basis, in Q3 2025.

● Available Liquidity – Following the capital raise and positive year-to-date operating cashflow, AbCellera has over $790 million in total cash balances and marketable securities, and over $100 million in available non-dilutive government funding, bringing total available liquidity to over $890 million to execute on AbCellera's strategy.

Business Metrics

At the end of Q3 2026, partners led 34 programs that AbCellera believes to be progressing and where AbCellera holds a downstream stake (down from 44 on December 31, 2025). In total, AbCellera held downstream stakes in 12 molecules in the clinic understood to be progressing on September 30, 2026.

Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 3:00 p.m. Pacific Time / 2:00 p.m. Pacific Standard Time / 5:00 p.m. Eastern Standard Time.

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit www.abcellera.com.

Financial statements

Income Statement

Three months ended September 30, — (Unaudited)

Three months ended September 30, – 2025Three months ended September 30, – 2026Nine months ended September 30, – 2025Nine months ended September 30, – 2026
Revenue:
Research fees8,81710,54919,52422,570
Licensing and royalty revenue1389010,751431
Total revenue8,95510,63930,27523,001
Operating expenses:
Research and development(1)55,02843,535136,736136,184
Sales, general, and administrative(1)24,95813,61366,01239,799
Depreciation and amortization5,2476,80616,04820,634
Total operating expenses85,23363,954218,796196,617
Loss from operations-76,278-53,315-188,521-173,616
Other income:
Interest and other-4,781-6,867-19,851-10,474
Grants and incentives-2,729-3,636-10,574-11,829
Total other income-7,510-10,503-30,425-22,303
Loss before income tax-68,768-42,812-158,096-151,313
Income tax recovery-11,649-2,054-20,629-11,963
Net loss-57,119-40,758-137,467-139,350
Foreign currency translation adjustment-41-2691,680813
Comprehensive loss-57,160-41,027-135,787-138,537
Net loss per share
Basic-0.19-0.13-0.46-0.45
Diluted-0.19-0.13-0.46-0.45
Weighted-average common shares outstanding
Basic298,875,174318,053,142298,366,169308,957,891
Diluted298,875,174318,053,142298,366,169308,957,891

Balance Sheet

December 31, 2025 — (Unaudited)

December 31, 2025September 30, 2026
Current assets:
Cash and cash equivalents128,513163,800
Marketable securities405,313600,624
Total cash, cash equivalents, and marketable securities533,826764,424
Accounts and accrued receivables58,29317,964
Restricted cash25,00025,000
Other current assets111,11368,770
Total current assets728,232876,158
Long-term assets:
Property and equipment, net428,003410,050
Intangible assets, net38,38138,389
Goodwill47,80647,806
Investments in equity accounted investees62,58063,845
Other long-term assets51,94863,616
Total long-term assets628,718623,706
Total assets1,356,9501,499,864
Current liabilities:
Accounts payable and other current liabilities50,78135,435
Deferred revenue13,52635,038
Total current liabilities64,30770,473
Long-term liabilities:
Operating lease liability137,403128,130
Deferred revenue3,50048,050
Deferred government contributions174,453180,275
Other long-term liabilities10,38310,436
Total long-term liabilities325,739366,891
Total liabilities390,046437,364
Shareholders’ equity:
Common shares: no par value, unlimited authorized shares at December 31, 2025 and September 30, 2026: 300,600,710 and 326,332,641 shares issued and outstanding at December 31, 2025 and September 30, 2026, respectively (Note 9)802,341996,188
Additional paid-in capital198,279238,565
Accumulated other comprehensive loss-4,234-3,421
Accumulated deficit-29,482-168,832
Total shareholders’ equity966,9041,062,500
Total liabilities and shareholders’ equity1,356,9501,499,864

Cash Flow

Nine months ended September 30, — (Unaudited)

Nine months ended September 30, – 2025Nine months ended September 30, – 2026
Cash flows from operating activities:
Net loss-137,467-139,350
Depreciation of property and equipment13,25717,842
Amortization of intangible assets2,7912,791
Amortization of operating lease right-of-use assets4,8535,422
Stock-based compensation42,88835,967
Other1,6015,599
Changes in operating assets and liabilities:
Research fees and grants receivable-15,95721,063
Income taxes receivable-19,79219,484
Accounts payable and accrued liabilities-2,286-13,311
Deferred revenue2,31666,062
Deferred grant income-2,834-6,717
Other assets14,0784,461
Net cash provided by (used in) operating activities-96,55219,313
Cash flows from investing activities:
Purchases of property and equipment-32,929-7,577
Purchase of marketable securities-324,704-624,840
Proceeds from marketable securities386,536429,162
Receipt of grant funding7,3667,184
Long-term investments and other assets-23,657-1,105
Net cash provided by (used in) investing activities12,612-197,176

AbCellera Forward-Looking Statements²... (truncated) any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.³

AbCellera Biologics Inc.

Condensed Consolidated Statements of Loss and Comprehensive Loss

(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)

(Unaudited)

(1)

Exclusive of depreciation and amortization⁴

AbCellera Biologics Inc.

Condensed Consolidated Balance Sheets

(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)

(Unaudited)⁵

AbCellera Biologics Inc.

Condensed Consolidated Statement of Cash Flows

(Expressed in thousands of U.S. dollars.)

(Unaudited)⁶

Inquiries

Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774

Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005

Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Source: AbCellera Biologics Inc.⁷

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · AbCellera Biologics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.